Basecamp Research hits $800M valuation with $140M AI drug discovery round
An AI-driven drug development company secured a $140 million funding round, pushing its valuation to $800 million. The oversubscribed investment was spearheaded by S32, with backing from Nvidia, Anthropic’s Anthology Fund, and others including the NATO Innovation Fund and Rockefeller Foundation.
Sources: economictimes.indiatimes.com
“The involvement of Nvidia and NATO’s fund underscores how AI drug discovery is drawing interest from both tech infrastructure giants and geopolitical stakeholders.”
What it means
This round reflects growing confidence in AI’s role in early-stage drug development, a space where failures are costly but potential payoffs are massive. The NATO Innovation Fund’s participation suggests strategic interest beyond pure financial returns, possibly tied to biosecurity or supply chain resilience. Whether Basecamp can translate its valuation into clinical wins will be the next test.
Read the original reporting
The outlets below did the original reporting.
- AI-based drug developer Basecamp valued at $800 million after $140 million funding round — economictimes.indiatimes.com
Related briefs
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.